Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Effective May 15, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) granted an exemption to BlackRock, Inc. (NYSE: BLK), together with its subsidiaries, affiliates and associates (collectively, “BlackRock”) under the Company’s Section 382 Rights Agreement, dated as of October 31, 2013, between the Company and Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”) following the determination by a designated committee of the Board of Directors (the … Continue reading Stocks To Watch: Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD), Galena Biopharma Inc (NASDAQ:GALE), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)

Jason Knox05/2205/22

Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Pfizer Inc. (NYSE:PFE)’s chief executive acknowledged Tuesday that a potential merger with AstraZeneca would lead to job losses, but promised to keep key research jobs in Britain as part of its $106 billion takeover bid. Pfizer Inc. (NYSE:PFE) stock performance was 0.24% in last session and finished the day at $29.20. Traded volume was 26.29million shares in the last session and the average volume of … Continue reading Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co., Inc. (NYSE:MRK), Gilead Sciences (NASDAQ:GILD), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis05/1405/14

Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

MannKind Corporation (NASDAQ:MNKD) loss of 14 cents per share in the first quarter of 2014 was wider than the Zacks Consensus Estimate by a penny but narrower than the year-ago loss by a penny. MannKind Corporation (NASDAQ:MNKD) did not generate any revenue in the first quarter of 2014, as in the year-ago quarter. Research and development (R&D) expenses remained flat at $26.2 million in the … Continue reading Hot Biotech Movers: MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), Chelsea Therapeutics (NASDAQ:CHTP)

Adam Keintzel05/1405/14

Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Investment analysts at JPMorgan Chase & Co. dropped their target price on shares of VIVUS (NASDAQ:VVUS) from $8.00 to $5.00 in a note issued to investors on Tuesday, Stock Ratings Network reports. JPMorgan Chase & Co.’s price target would indicate a potential downside of 10.15% from the company’s current price. VIVUS, Inc. (NASDAQ:VVUS)stock performance was 7.23% in last session and finished the day at $ … Continue reading Hot Biotech Stocks: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA), Gilead Sciences (NASDAQ:GILD)

Jayne Crisman05/0705/07

Gilead Sciences GILD NASDAQ:GILD

Analysis, BioTech, Featured

Active Stocks: Endocyte (NASDAQ:ECYT), Gilead Sciences, Inc. (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA), Immunomedics (NASDAQ:IMMU)

Endocyte (NASDAQ:ECYT)’s shares saw strong trading volume on Friday after the company announced better than expected quarterly earnings, American Banking and Market News reports. 13,778,961 shares changed hands during trading, an increase of 624% from the previous session’s volume of 1,903,723 shares. Endocyte, Inc. (NASDAQ:ECYT) stock performance was 61.91% in last session and finished the day at $ 6.62. Traded volume was 17,639,435 shares in … Continue reading Active Stocks: Endocyte (NASDAQ:ECYT), Gilead Sciences, Inc. (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA), Immunomedics (NASDAQ:IMMU)

Adam Keintzel05/0505/05

Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

JPMorgan Chase & Co. (NYSE:JPM) EVP Gordon Smith sold 71,952 shares of the stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $54.91, for a total value of $3,950,884.32. Following the transaction, the executive vice president now directly owns 143,905 shares of the company’s stock, valued at approximately $7,901,824. JPMorgan Chase & Co. (NYSE:JPM) stock … Continue reading Recent Insider Selling: JPMorgan Chase (NYSE:JPM), Micron Technology (NASDAQ:MU), Gilead Sciences (NASDAQ:GILD), Arena Pharmaceuticals (NASDAQ:ARNA)

John Meady04/1704/17